Important news for pharma companies: the Bolar exemption is about to be broadened
Before a medicinal product can be marketed in the UK, it must first be given regulatory approval following clinical tests to show that the product is safe and effective. Producers of generic medicines can use the original manufacturer’s approval provided they can show that the generic product is bioequivalent to the approved medicine. However, the generic producer may face an action for patent infringement if it conducts clinical trials on a patented product before the expiry of the patent. The Bolar exemption means that such clinical trials will not constitute patent infringement.
The exemption sits within two EU directives — the directive on medicinal products for human use and a directive on veterinary medicinal products — and the relevant provisions are transposed into English law by section 60(5) of the Patents Act 1977.
The government has been consulting on broadening the scope of the Bolar exemption and, to that end, the draft Legislative Reform (Patents) Order 2014 was laid before Parliament on 6 May 2014. Broadly, the draft order will extend the Bolar exemption to cover the conducting of necessary trials and health technology assessments of all drugs, both novel and generic, and all applications for marketing authorisations…
Click on the link below to read the rest of the Walker Morris briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Walker Morris
News from The Lawyer
Briefings from Walker Morris
A number of market features gives rise to an adverse effect on competition, says CMA.
The FBI ’Darkode’ arrests are just the tip of the iceberg. This briefing highlights risks to you in five key areas.
Analysis from The Lawyer
Which firms are cutting it in this era of slimline rosters, and who are the GC new brooms making clean sweeps? The Lawyer can reveal all
The law school war shows no signs of ending. But we have, perhaps, reached the end of the beginning.